Rheumatology, Bucks Healthcare NHS Trust, Aylesbury, UNITED KINGDOM Introduction: Cryoglobulins are immunoglobulins in the serum that precipitate at temperatures below 37 C and can be classified into three groups. Type 1 cryoglobulinaemia occurs in approximately 5-25% of cases and develops in the setting of protein secreting monoclonal gammopathies such as a monoclonal gammopathy of undetermined significance (MGUS) or a B-cell lineage malignancy for example multiple myeloma, Waldenströ m macroglobulinemia, or chronic lymphocytic leukaemia. Cryoglobulinaemia remains asymptomatic in the majority but can lead to immune complex tissue deposition, causing cryoglobulinaemic small and medium vessel vasculitis in up to 15%. Type I cryoglobulinemia classically produces symptoms secondary to vascular occlusion and thrombosis by the cryoprecipitate such as digital ischemia, livedo reticularis, and skin necrosis. Livedo reticularis, vascular occlusion and digital ischaemia are also features of anti-phospholipid syndrome (APLS). It is also noted that there are reports of APLS in the setting of malignancy includingmyeloproliferative disorders. Case description: We describe the case of a 44 year old female nonsmoker, who presented to the vascular surgeons with ischaemic right 2 nd and 4 th toes and swollen erythematous legs. CT angiogram did not reveal macrovascular occlusion and a subsequent MRA lower limb confirmed there was no significant arterial disease. She had a normal echocardiogram with no evidence of emboli. Due to her history of obstetric APLS she was anticoagulated with warfarin under haematology guidance. This diagnosis was based on 5 first trimester miscarriages following 1 successful pregnancy, one positive lupus anticoagulant and a weakly positive anti-cardiolipin IgG antibody (28 units/ml). She had a second successful pregnancy covered with LMWH. Shortly after discharge, she developed a livedo rash on her lower limbs which rapidly progressed to multiple, excruciatingly painful, punched-out ulcers. She had no additional symptoms and was systemically well. However, her right 2nd and 4th toes were now gangrenous. Investigations at that time showed normal FBC and UþE, ESR 52 and CRP 4.9. Her serology revealed a weakly positive lupus anticoagulant (ratio 1.43), and negative anticardiolipin and B2GP1 antibodies. Her ANA, ENA, dsDNA, RF and ANCA were negative. Complement C3 was normal mg/dl and C4 low mg/dl. Interestingly there was a monoclonal IgG band identified with no significant secondary hypogammaglobulinaemia. Urinalysis was negative for casts and proteinuria. She was commenced on prednisolone 20mg for vasculitic ulcers secondary to APLS. She initially improved and the gangrenous toes were surgically amputated. Histology showed severe acute inflammation of the soft tissues, osteomyelitis and small vessel vasculitis. Azathioprine was commenced cautiously at 25mg daily due to a borderline TPMT level. However, her leg ulcers deteriorated reducing prednisolone to 12.5mg daily and she also developed a new purpuric rash on her lower limbs. This progressed to extensive cutaneous necrosis and new right 3rd toe ischaemia. There was no improvement despite 2 pulses of 500mg intravenous methyl prednisolone and iloprost infusion. She underwent amputation of the toe with the histology demonstrating widespread small vessel thrombosis with ischaemic changes but no vasculitic features. Further investigation revealed the presence of cryoglobulins (3% on quantification) in association with an IgG kappa paraprotein of 6g/ L with a kappa lambda ratio of 9.92. This lead to a diagnosis of type 1 cryoglobulinaemia. Her bone marrow aspirate showed 3% plasma cells with an abnormal lymphoplasmacytoid infiltrate. There was no excess CD138/CD38 cells and no abnormal B cell clone on bone marrow immunophenotyping. CTCAP did not show any evidence of a solid malignancy. Her hepatitis B and C serology was negative and C4 remained low at 8.3 mg/dl with no additional change in her previous serology. Warfarin was stopped; she was started on treatment dose LMWH and she commenced 60mg prednisolone. She began weekly plasmapheresis and 6 cycles of cyclophosphamide 15mg/kg for cryoglobulinaemic vasculitis. Treatment was complicated by significant wound infection and a skin graft was planned once stable. She also developed new joint synovitis requiring an increase of prednisolone to 40mg daily. Her cryocrit levels continued to rapidly accumulate post plasma exchange. After completing 5 cycles of cyclophosphamide a repeat bone marrow biopsy was performed. This showed 10% plasma cells positive for CD138 and CD56 with kappa light chain restriction and a diagnosis of myeloma was confirmed. She was consented to start treatment with Bortezomib chemotherapy. Unfortunately, she was admitted one week later with sepsis and an acute kidney injury (Creatinine 279 from a baseline of 60). Wound swab from her legs grew an ESBL-producing strain of Escherichia Coli and she was treated with Meropenem.During admission shedeveloped reduced GCS with a dense right sided hemiparesis. Urgent CT brain scan showed a large volume acute parenchymal haemorrhage throughout the left frontal lobe, withintraventricular ruptureincludingthefourthventricle andgeneralised oedema. Despite emergency neurosurgical intervention, she deteriorated with another cerebral bleed and passed away. Discussion: In patients with monoclonal (type I) cryoglobulin associated with a lymphoproliferative disorder, the treatment is focused on the underlying malignancy and the risk or presence of complications such as hyperviscosity syndrome. Patientswith hyperviscosity may require treatmentwithplasmaexchange.Treatmentforvasculitisincludesglucocorticoids and cyclophosphamide, Rituximab is effective in mixed cryoglobulinaemia, however in type I the efficacy is less clear. The use of other drugs, including thalidomide, lenalinomide, and bortezomib-based regimens may also be useful. The therapeutic challenge was to control our patient's limb threatening skin manifestions whilst a diagnosis of haematological malignancy was confirmed. The cutaneous lesions were difficult to treat despite multiple therapies and plasmapheresis was not effective in achieving an adequate response. Concurrent infection also proved a challenging factor in giving further immunosuppression. Without a correct diagnosis we could not proceed with the appropriate treatment of the underlying disorder. There is good evidence for the use bortezomib, a proteasome inhibitor that inhibits angiogenesis and production of paraproteins, in treatment in type-1 cryoglobulinemic vasculitis, unfortunately our patient passed away prior to commencing treatment. Introduction: We present a rare case of macrophage activation syndrome in apreviously well 53 year old male with apersistently unclear aetiology. Whilst the patient's response to anakinra has been consistent with underlying adult-onset Still's disease, the diagnostic criteria were not clearly met and a concomitant new diagnosis of ankylosing spondylitis raises the possibility of an unusual rheumatological trigger. Case description: A 53 year old male was referred to the infectious diseases team with a three-month history of pyrexia of unknown origin, together with intermittent sweating, rigors and dyspnoea on exertion. The patient had recently been treated successfully for chronic prostatitis with ciprofloxacin although it was felt that this did not entirely explain hissymptoms. Past medical history included hypertension but was otherwise unremarkable. Viral and bacterial serology, echocardiogram, plain chest films and lumbar puncture had no abnormal findings. An autoimmune screen was similarly negative and the patient was referred for wholebody FDG PET which showed no abnormal tracer uptake. The patient was subsequently reviewed by rheumatology and, on further questioning, reported stiffness of the back, neck and shoulders. On examination, there was reduced chest expansion, decreased cervical spinal flexion androtation andSchober'stest was positive at 3cm.MRIof the spinesubsequently revealed sacroiliitis and a diagnosis of ankylosing spondylitis was made. On outpatient review, the patient was found to be profoundly diaphoretic, tachypnoeic and tachycardic with a significantly elevated CRP. The patient reported worsening back pain, fevers and a swollen left knee together with an unwitnessed prior rash. The patient was admitted fromclinic and,following anincreaseinoxygenrequirements,wassubsequently transferred to ITU, where he was intubated. Whilst repeat serology and virology remained negative, plain chest x-ray revealed changes consistent with a rapidly-progressing ARDS and the patient was commenced on empirical antibiotic treatment for presumptive tuberculosis given the initial presentation. Over subsequent days, CRP remained significantly elevated over 300 despite antibiotics and aworsening thrombocytopaenia developed. Bone marrow and trephine biopsy revealed striking haemophagocytosis and the patient required full respiratory support together with cardiac inotropes and haemofiltration. The impression remained of a possible sepsis-driven systemic inflammatory response and multiple antimicrobial therapy continued. However, the patient remained refractory to treatment, including with etoposide, and a primary inflammatory process became more likely as an aetiology. Adult-onset Still's disease was raised as a differential given the possible history of fleeting arthritis and rash. In this context, the patient's haemophagocytic lymphohistiocytosis was thought to be macrophage-activation syndrome (MAS) and due to an underlying cytokine storm process. The lack of diagnostic certainty made the decision for immunosuppression difficult and the case was discussed with neurology, intensivists and infectious disease. The consensus was that sepsis of unknown source could not be excluded although, compounding this was the fact that the patient failed to respond to etoposide and high dose intravenous steroids. It was agreed to commence anakinra which was thought to be safe in the context of possible sepsis. The patient became afebrile twelve hours after subcutaneous administration and CRP reduced to 22 over subsequent days. The patient remained in ITU for a 76-day admission with multiorgan dysfunction and slow weaning necessitated an EEG which demonstrated periodic seizure activity. MRI brain confirmed multiple lesions with leptomeningeal enhancement and these were thought to be neurological sequelae of MAS. The patient was commenced on anticonvulsant medication. The patient continued to improve despite multiple pneumothoraces and a left subclavian deep vein thrombosis as a result of intervention. He also suffered from ITU-myopathy which required a period of physical rehabilitation but was discharged from hospital still on anakinra and on a weaning regimen of oral steroids. He has now been switched to methotrexate and remains clinically well. Discussion:This complex case clearly raises numerous interesting diagnostic challenges and uncertainties. The diagnosis of MAS crucially includes the histological finding of HLH on bone marrow biopsy which was present in this case. However, many of the other diagnostic features such as hepatosplenomegaly, hypofibrinogenaemia, multiple line cytopaenia and hyperferritinaemia were not found. MAS is most commonly secondary to juvenile idiopathic arthritis and, whilst evidence suggests it can be found with other rheumatological disease, there are very few cases to support ankylosing spondylitis as a cause. The patient did not convincingly fulfil a diagnosis of adult-onset Still's given a vague history of rash and persistently normal ferritin, although the presence of arthritis and ongoing pyrexia would obviously not entirely preclude this as an underlying cause, as would the striking clinical response to anakinra treatment. This case raises the rare possibility of ankylosing spondylitis driving a severe systemic inflammatory response but also questions what is known about the interplaybetween adult-onset Still's and MAS. Key Learning Points: The need for a multi-disciplinary approach with other specialties, especially infectious disease, when investing and treating complex patient with systemic inflammatory responses to fully exclude sepsis as a driving factor. To consider and explore all possible rheumatological conditions as a trigger for macrophage activation syndrome with the subsequent implications forpossible treatment options. Disclosure: J.S. Gill: None. S. Black: None. C. Raine: None. P. Mangat: None. ). X-rays of the hands, feet and chest were normal. She was diagnosed with a seronegative inflammatory arthritis and treated with sulfasalazine and prednisolone 7.5mg daily with good response. A year later she presented acutely with pleuritic chest pain, polyuria and weight loss. She was noted to have erythema nodosum and CT pulmonary angiogram excluded pulmonary embolus but demonstrated prominent mediastinal lymphadenopathy. Renal function was impaired (creatinine 141lmol/L) and serum ACE mildly raised (70). Calcium was normal (2.47mmol/L), urine dipstick negative for blood and protein, serum and urine protein electrophoresis negative and ultrasound of the renal tract normal. Diabetes mellitus was excluded with a normal fasting glucose (5.4) and HbA1c 41mmol/mol. A water deprivation test failed to concentrate urine nor improve with desmopressin indicating nephrogenic diabetes insipidus (DI). Subsequent renal biopsy demonstrated granulomatous tubulointerstitial nephritis, appearances consistent with sarcoid (image available but not able to upload to abstract submission). The patient was commenced on prednisolone 60mg daily and methotrexate with a rapid and marked improvement in symptoms and renal function (ESR 5mm/h, creatinine 93lmol/L and serum ACE 17). Discussion: Sarcoidosis may present with an inflammatory arthritis, and up to one third of patients are reported to have musculoskeletal involvement. Up to 40% of patients may have renal disease. Hypercalcemia is the most prevalent cause of renal dysfunction in sarcoidosis followed by granulomatous interstitial nephritis (GIN), tubular dysfunction, obstructive uropathy, granulomatous angiitis and rarely glomerular disease. The true incidence of renal involvement in sarcoid is unknown, as is progression to chronic kidney disease. Hypercalcaemia and hypercalciuria is the predominant cause of renal disease in sarcoid, and if left untreated will result in progressive tubulointerstitial inflammation, nephrocalcinosis and CKD. Granulomatous interstitial nephritis was identified in 7-23% of patients with sarcoidosis in an autopsy study, although many were clinically silent. Nephrogenic DI in the context of sarcoid is an extremely unusual presentation. There are only two previous published reports, one in the setting of pulmonary sarcoidosis with DI due to hypercalcaemia in 2003, and another case from 1965 (normocalcaemic). Proposed treatment pathways for GIN in sarcoid include glucocorticoids, followed by azathioprine or mycophenolate mofetil, with the final step including biologic treatments including infliximab (3 previous case reports of using infliximab with positive outcomes). Transplantation has been reported in renal sarcoidosis, however in a French series of 18 patients, 17% had recurrence of disease, but the long termeffect of this remains unknown. Key Learning Points: We have described a case of seronegative inflammatory arthritis which predated the onset of more classical features of systemic sarcoidosis presenting with erythema nodosum, mediastinal
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